Clinical Trial Update: Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer. [Phase 2]

View source ↗

Summary

Open-label, Phase 2 dose-finding trial to assess antibody response to G17DT in gastric cancer patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• G17DT

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED